SUMATRIPTAN SUCCINATE tablet

Krajina: Spojené štáty

Jazyk: angličtina

Zdroj: NLM (National Library of Medicine)

Aktívna zložka:

SUMATRIPTAN SUCCINATE (UNII: J8BDZ68989) (SUMATRIPTAN - UNII:8R78F6L9VO)

Dostupné z:

Asclemed USA, Inc.

Spôsob podávania:

ORAL

Typ predpisu:

PRESCRIPTION DRUG

Terapeutické indikácie:

Sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.   Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks. • Sumatriptan tablets are not indicated for the prevention of migraine attacks. • Safety and effectiveness of sumatriptan tablets have not been established for cluster headache. Sumatriptan tablets are contraindicated in patients with: • Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions ( 5.1 )] • Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (

Prehľad produktov:

Sumatriptan tablets USP, 50 mg are white, round, biconvex film-coated tablets debossed with “RDY” on one side and “292” on the other side. The tablets are supplied in unit of use blister pack of 9’s.   Unit of use blister pack of 9 (1 x 9) NDC 76420-093-09 (relabeled from NDC 55111-292-09) Store at 20 ° to 25°C (68 ° – 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). 

Stav Autorizácia:

Abbreviated New Drug Application

Súhrn charakteristických

SUMATRIPTAN SUCCINATE- SUMATRIPTAN SUCCINATE TABLET
ASCLEMED USA, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
SUMATRIPTAN TABLETS SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR SUMATRIPTAN TABLETS.
SUMATRIPTAN TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1992
INDICATIONS AND USAGE
Sumatriptan is a serotonin (5-HT
) receptor agonist (triptan) indicated for acute treatment of migraine
with or without
aura in adults. ( 1)
Limitations of Use:
Use only if a clear diagnosis of migraine headache has been
established. ( 1)
Not indicated for the prophylactic therapy of migraine attacks. ( 1)
Not indicated for the treatment of cluster headache. ( 1)
DOSAGE AND ADMINISTRATION
Single dose of 25 mg, 50 mg, or 100 mg tablet.( 2.1)
A second dose should only be considered if some response to the first
dose was observed. Separate doses by at least 2
hours. ( 2.1)
Maximum dose in a 24-hour period: 200 mg. ( 2.1)
Maximum single dose should not exceed 50 mg in patients with mild to
moderate hepatic impairment. ( 2.2)
DOSAGE FORMS AND STRENGTHS
Tablets:50 mg ( 3)
CONTRAINDICATIONS
History of coronary artery disease or coronary artery vasospasm ( 4)
Wolff-Parkinson-White syndrome or other cardiac accessory conduction
pathway disorders ( 4)
History of stroke, transient ischemic attack, or hemiplegic or basilar
migraine ( 4)
Peripheral vascular disease ( 4)
Ischemic bowel disease ( 4)
Uncontrolled hypertension ( 4)
Recent (within 24 hours) use of another 5-HT
agonist (e.g., another triptan) or of an ergotamine-containing
medication.
( 4)
Concurrent or recent (past 2 weeks) use of monoamine oxidase-A
inhibitor. ( 4)
Hypersensitivity to sumatriptan (angioedema and anaphylaxis seen). (
4)
Severe hepatic impairment. ( 4)
WARNINGS AND PRECAUTIONS
Myocardial ischemia/infarction and Prinzmetal’s angina: Perform
cardiac evaluation in patients with multiple
cardiovascular risk factors. ( 5.1)
Arrhythmias: Discontinue sumatriptan if occurs. ( 5.2)
Chest/th